Immune cell 'Packages' injected into tumors: a new hope for advanced cancer?
NCT ID NCT07563972
First seen May 15, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. The main goal is to check for side effects, but researchers will also watch for any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mechanobiologically reprogrammed macrophage-derived exosomes
What this could lead to
If it works, this could point toward a new way to treat advanced solid tumors by reprogramming immune cells to attack cancer.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, so safety and effectiveness are not yet known. The treatment is injected directly into tumors, which may not work for all cancer types or locations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.